|
1
|
Christensen HN: Role of amino acid
transport and countertransport in nutrition and metabolism. Physiol
Rev. 70:43–77. 1990.PubMed/NCBI
|
|
2
|
Palacín M, Estévez R, Bertran J and
Zorzano A: Molecular biology of mammalian plasma membrane amino
acid transporters. Physiol Rev. 78:969–1054. 1998.PubMed/NCBI
|
|
3
|
Kanai Y, Segawa H, Miyamoto Ki, Uchino H,
Takeda E and Endou H: Expression cloning and characterization of a
transporter for large neutral amino acids activated by the heavy
chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yanagida O, Kanai Y, Chairoungdua A, Kim
DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, et
al: Human L-type amino acid transporter 1 (LAT1): Characterization
of function and expression in tumor cell lines. Biochim Biophys
Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prasad PD, Wang H, Huang W, Kekuda R,
Rajan DP, Leibach FH and Ganapathy V: Human LAT1, a subunit of
system L amino acid transporter: Molecular cloning and transport
function. Biochem Biophys Res Commun. 255:283–288. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim DK, Ahn SG, Park JC, Kanai Y, Endou H
and Yoon JH: Expression of L-type amino acid transporter 1 (LAT1)
and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its
precursor lesions. Anticancer Res. 24:1671–1675. 2004.PubMed/NCBI
|
|
7
|
Honjo H, Kaira K, Miyazaki T, Yokobori T,
Kanai Y, Nagamori S, Oyama T, Asao T and Kuwano H:
Clinicopathological significance of LAT1 and ASCT2 in patients with
surgically resected esophageal squamous cell carcinoma. J Surg
Oncol. 113:381–389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ichinoe M, Mikami T, Yoshida T, Igawa I,
Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H and Okayasu I: High
expression of L-type amino-acid transporter 1 (LAT1) in gastric
carcinomas: Comparison with non-cancerous lesions. Pathol Int.
61:281–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Segawa A, Nagamori S, Kanai Y, Masawa N
and Oyama T: L-type amino acid transporter 1 expression is highly
correlated with gleason score in prostate cancer. Mol Clin Oncol.
1:274–280. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaira K, Oriuchi N, Imai H, Shimizu K,
Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, et
al: Prognostic significance of L-type amino acid transporter 1
expression in resectable stage I–III nonsmall cell lung cancer. Br
J Cancer. 98:742–748. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaira K, Sunose Y, Ohshima Y, Ishioka NS,
Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, et
al: Clinical significance of L-type amino acid transporter 1
expression as a prognostic marker and potential of new targeting
therapy in biliary tract cancer. BMC Cancer. 13:4822013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaira K, Sunose Y, Arakawa K, Ogawa T,
Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, et
al: Prognostic significance of L-type amino-acid transporter 1
expression in surgically resected pancreatic cancer. Br J Cancer.
107:632–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Furuya M, Horiguchi J, Nakajima H, Kanai Y
and Oyama T: Correlation of L-type amino acid transporter 1 and
CD98 expression with triple negative breast cancer prognosis.
Cancer Sci. 103:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le Bihan S, Marsaud V, Mercier-Bodard C,
Baulieu EE, Mader S, White JH and Renoir JM: Calcium/calmodulin
kinase inhibitors and immunosuppressant macrolides rapamycin and
FK506 inhibit progestin-and glucocorticosteroid receptor-mediated
transcription in human breast cancer T47D cells. Mol Endocrinol.
12:986–1001. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin J, Adam RM, Santiestevan E and Freeman
MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth
factor-activated cell survival pathway in LNCaP human prostate
carcinoma cells. Cancer Res. 59:2891–2897. 1999.PubMed/NCBI
|
|
17
|
Luan FL, Hojo M, Maluccio M, Yamaji K and
Suthanthiran M: Rapamycin blocks tumor progression: Unlinking
immunosuppression from antitumor efficacy. Transplantation.
73:1565–1572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaira K, Oriuchi N, Imai H, Shimizu K,
Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, et
al: L-type amino acid transporter 1 (LAT1) is frequently expressed
in thymic carcinomas but is absent in thymomas. J Surg Oncol.
99:433–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaira K, Oriuchi N, Imai H, Shimizu K,
Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, et
al: L-type amino acid transporter 1 and CD98 expression in primary
and metastatic sites of human neoplasms. Cancer Sci. 99:2380–2386.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ebara T, Kaira K, Saito J, Shioya M, Asao
T, Takahashi T, Sakurai H, Kanai Y, Kuwano H and Nakano T: L-type
amino-acid transporter 1 expression predicts the response to
preoperative hyperthermo-chemoradiotherapy for advanced rectal
cancer. Anticancer Res. 30:4223–4227. 2010.PubMed/NCBI
|
|
21
|
Martins SF, Amorim R, Mota SC, Costa L,
Pardal F, Rodrigues M and Longatto-Filho A: Ki-67 expression in crc
lymph node metastasis does not predict survival. Biomed Res Int.
2015:1316852015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Allegra CJ, Paik S, Colangelo LH, Parr AL,
Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N and Wieand HS:
Prognostic value of thymidylate synthase, Ki-67, and p53 in
patients with Dukes' B and C colon cancer: A national cancer
institute-national surgical adjuvant breast and bowel project
collaborative study. J Clin Oncol. 21:241–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jansson A and Sun XF: Ki-67 expression in
relation to clinicopathological variables and prognosis in
colorectal adenocarcinomas. APMIS. 105:730–734. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi L, Luo W, Huang W, Huang S and Huang
G: Downregulation of L-type amino acid transporter 1 expression
inhibits the growth, migration and invasion of gastric cancer
cells. Oncol Lett. 6:106–112. 2013.PubMed/NCBI
|
|
25
|
Hirayama A, Kami K, Sugimoto M, Sugawara
M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, et
al: Quantitative metabolome profiling of colon and stomach cancer
microenvironment by capillary electrophoresis time-of-flight mass
spectrometry. Cancer Res. 69:4918–4925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Segawa H, Fukasawa Y, Miyamoto K, Takeda
E, Endou H and Kanai Y: Identification and functional
characterization of a Na+-independent neutral amino acid
transporter with broad substrate selectivity. J Biol Chem.
274:19745–19751. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nicklin P, Bergman P, Zhang B,
Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson
C, et al: Bidirectional transport of amino acids regulates mTOR and
autophagy. Cell. 136:521–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hara K, Yonezawa K, Weng QP, Kozlowski MT,
Belham C and Avruch J: Amino acid sufficiency and mTOR regulate p70
S6 kinase and eIF-4E BP1 through a common effector mechanism. J
Biol Chem. 273:14484–14494. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Campbell LE, Miller CM and Proud
CG: Amino acid availability regulates p70 S6 kinase and multiple
translation factors. Biochem J. 334:261–267. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oda K, Hosoda N, Endo H, Saito K,
Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y and
Endou H: L-type amino acid transporter 1 inhibitors inhibit tumor
cell growth. Cancer Sci. 101:173–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaira K, Oriuchi N, Otani Y, Shimizu K,
Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, et
al: Fluorine-18-alpha-methyltyrosine positron emission tomography
for diagnosis and staging of lung cancer: A clinicopathologic
study. Clin Cancer Res. 13:6369–6378. 2007. View Article : Google Scholar : PubMed/NCBI
|
